Harvard Director of Global Health Catalyst at the World-Renowned Dana Farber/Harvard Cancer Center States: Cannabis Science Presentation and Discussions a Great Success for Mutually Beneficial Partnership Opportunities with Harvard Medical School
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, proudly announced that following its presentation to Harvard Medical School, the Harvard Director of Global Health Catalyst at the World-Renowned Dana Farber/Harvard Cancer Center (DF/HCC), Dr. Wilfred F. Ngwa, stated: "The Cannabis Science Presentation and Discussions was a Great Success and will lead to mutually beneficial partnership opportunities between Cannabis Science and Harvard Medical School."
Dr. Wilfred F. Ngwa, Director of Global Health Catalyst at the world-renowned Dana Farber/Harvard Cancer Center, initiated the discussions and will lead the way to design and implement future joint research and mutually beneficial partnership opportunities.
Dr. Ngwa stated, "I must say that we were pleasantly surprised with the depth of knowledge, clearly targeted missions, and direct plan of action delivered by Cannabis Science. It was certainly refreshing and clear. We invited Mr. Dabney and his team to discuss the drug development success and progress the company had made over the years. Partnerships between the CBIS team and scientists here at the DF/HCC are expected to bring a deeper understanding of the potential effectiveness of cannabinoids in the treatment of cancer and other chronic diseases. We will outline the critical motivations for our research partnership with a view of successfully publishing these in a high impact peer-reviewed medical journal."
Mr. Dabney presented the discussions, and together with Mr. Melvin F. Foote of the Constituency for Africa, and Dr. Allen A. Herman, the Chief Medical Officer of CBIS delivered an extensive overview of CBIS and the Cannabis Science Research Foundation; summarizing the science of cannabinoids, targeting various critical ailments and confirming the ability to kill cancer cells and enhance the therapeutic management of various cancers; and engaged members of the Harvard faculty in deliberating approaches to forming a research and drug development partnership between CBIS, Inc. and Dana Farber/Harvard Cancer Center.
Dr. Herman reflected, "During the roundtable discussion after our presentation, we had the opportunity to discuss potential pre-clinical, and clinical research programs and goals with the scientists at DF/HCC . Our drug development targeting will be executed by the new partnership and is expected to alter the dynamics of phyto-pharmaceutical development, particularly in the areas of clinical trial design and program implementations. Our discussions of these focal areas with Dr. Wil Ngwa and his colleagues were incisive and very positive, and we have started the process of planning a series of exciting and mutually beneficial partnership opportunities."
"With the support of a strong team of scientists at what is quite possibly the world's most prestigious cancer research institution, Cannabis Science hopes to bring new treatments from research to FDA approval much more quickly. The strength of this partnership is underscored by a deep knowledge of the approval processes at the Food and Drug Administration (FDA). GW Pharmaceuticals was the first cannabis based company to introduce pharmaceuticals through the FDA, enabling them to gain market approval with a cannabis-derived drug, and in many ways, they have paved the way for us to work towards our own FDA approval on many of our treatments. We believe that working closely with DF/HCC, one of the world's top cancer research organizations, will be a game-changer. We truly believe that we are at the forefront of an exciting opportunity to reach a much wider range of patients than ever before with our drugs," said Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science, Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.